There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Siemens Healthineers AG (SEMHF – Research Report) and Lineage Cell Therapeutics (LCTX – Research Report) with bullish sentiments.
Siemens Healthineers AG (SEMHF)
UBS analyst Graham Doyle maintained a Buy rating on Siemens Healthineers AG today and set a price target of EUR59.00. The company’s shares closed last Friday at $52.76.
Doyle has an average return of
According to TipRanks.com, Doyle is ranked #7155 out of 8141 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Siemens Healthineers AG with a $59.26 average price target, which is a 12.3% upside from current levels. In a report issued on November 22, Barclays also maintained a Buy rating on the stock with a EUR64.00 price target.
Lineage Cell Therapeutics (LCTX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lineage Cell Therapeutics today and set a price target of $7.00. The company’s shares closed last Friday at $1.42.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lineage Cell Therapeutics with a $5.40 average price target, a 267.3% upside from current levels. In a report issued on November 14, Robert W. Baird also maintained a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SEMHF:
- AbbVie’s (NYSE:ABBV) Loss Could be CVS’s (NYSE:CVS) Gain
- China COVID-19 Protests Take Crude Back to January Lows; EU Talks on Oil Price Cap Stall
- Analysts Offer Insights on Technology Companies: Intuit (INTU) and Activision Blizzard (ATVI)
- Apple Likely to Fall Short of 6 Million iPhone Pros
- Chevron (NYSE:CVX) Secures License to Pump Oil Now; Markets Will See It Later